Skip to main content
OpenTrials
Completed

NCT Number: NCT00595075

Ramelteon for a Nap Prior to a Night Shift

Night shift-workers are often advised to take a prophylactic nap prior to starting the shift in order to improve alertness and performance. However, individuals often report difficulty initiating and maintaining sleep at that time of the day secondary to the alerting influence of the near-24 hour circadian rhythm (biological clock). A sleep-promoting medication may improve the quality of an evening nap and subsequent alertness and performance during a night shift. We will use Ramelteon, a melatonin agonist that is FDA approved for insomnia, in order to test the following hypotheses:

1. ramelteon, compared with placebo, will significantly increase sleep efficiency during a 2-hour nap; 2. sleep inertia, as assessed by neurobehavioral tests and subjective and objective sleepiness assessments will not be significantly increased after ramelteon treatment compared with placebo treatment; and 3. neurobehavioral performance, subjective and objective sleepiness, and subjective mood during a simulated 8-hour night shift will be significantly improved when ramelteon is given prior to a prophylactic nap compared to a prophylactic nap with placebo.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged between 18-35 years;
  • Non-smoking for at least 6 months;
  • Healthy (no medical, psychiatric or sleep disorders);
  • No clinically significant deviations from normal in medical history, vital signs, physical examination, blood chemistry and hematology, and ECG;
  • Women of childbearing potential must agree to use an acceptable method of birth control, and must have a negative serum pregnancy test;
  • Body mass index of > 18 or < 30 kg/m∧2;
  • No drugs or medication likely to affect sleep or alertness, as determined by the investigators;
  • Habitual caffeine consumption < 300 mg per day on average;
  • Habitual alcohol consumption < 10 alcoholic units per week on average.

Exclusion criteria

  • History of alcohol or substance abuse;
  • Positive result on drugs of abuse screening;
  • Current or past history of sleep disorders, including but not limited to obstructive sleep apnea, or any significant sleep complaint;
  • Psychiatric disorder, including a history of depression or dysthymia (characterized by depressed mood on the majority of days for at least two years);
  • Recent acute or chronic medical disorder, including but not limited to hepatic impairment and severe chronic obstructive pulmonary disease;
  • History of intolerance or hypersensitivity to melatonin or melatonin agonists;
  • Pregnancy or lactation;
  • Shift work;
  • Transmeridian travel (2 or more time zones) in past 2 months;
  • Any other scientific or medical reason, as determined by the PI, such as non-compliance with protocol or intolerance to inpatient study conditions.

Treatment and study plan

Ramelteon

Drug

Ramelteon 8 mg tablet by mouth x 1 dose

Other names: Rozerem

Placebo

Drug

placebo identical in appearance to active experimental drug x 1 dose

Primary outcomes

  1. Sleep Efficiency

    Time frame: 2 hours

    total sleep time/time in bed * 100% (higher values indicate better outcome)

Other outcomes

  1. Post-nap Assessment - Visual Analog Scale

    Time frame: 71 minutes

    numerical scale of increasing alertness from 0-100 (higher values are better outcome)

  2. Post Nap Assessment - Karolinska Sleepiness Scale

    Time frame: 71 minutes

    numerical scale of increasing sleepiness from 1-9 (higher values indicate worse outcome)

  3. Post Nap Assessment - Digit Symbol Substitution Test (Correct Answers)

    Time frame: 71 minutes

    A cognitive throughput task consisting of matching symbols to numerical keys; higher numbers indicate a better score

  4. Post Nap Assessment - Karolinska Drowsiness Test

    Time frame: 71 minutes

    EEG spectral analysis of 5.5-9.0 Hz frequency activity (theta low-frequency alpha), with higher activity indicating increased drowsiness and worse outcome

  5. Psychomotor Vigilance Task - Median Reaction Time

    Time frame: 8 hours

    Visual-motor reaction time in which participants hit a button on a response box as fast as possible in response to a visual target (lower values indicate better outcome)

  6. Psychomotor Vigilance Task - Number of Lapses

    Time frame: 8 hours

    Number of trials per test battery with a reaction time >0.5 seconds (higher values indicate worse outcome)

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Collaborators

  • Takeda

Registry information

Official study title

Effects of Ramelteon on Sleep and Neurobehavioral Performance in a Simulated Night Shift Preceded by a Sleep Opportunity

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Jan 16, 2008
Registry last updated
Oct 30, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.